Beigene Ltd (NASDAQ:BGNE) shares fell 4.2% during trading on Friday . The stock traded as low as $26.24 and last traded at $26.24, with a volume of 62,904 shares changing hands. The stock had previously closed at $27.40.

Several brokerages have commented on BGNE. Zacks Investment Research raised shares of Beigene from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. Cowen and Company reissued a “buy” rating on shares of Beigene in a report on Thursday, May 12th. Finally, Morgan Stanley raised their price target on shares of Beigene from $39.00 to $42.00 in a report on Friday, April 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $39.67.

The company’s market capitalization is $593.50 million. The stock has a 50 day moving average price of $29.15 and a 200-day moving average price of $28.87.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.97) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.92. The company had revenue of $0.70 million for the quarter. The company’s quarterly revenue was down 50.0% on a year-over-year basis. On average, analysts predict that Beigene Ltd will post ($3.17) earnings per share for the current fiscal year.

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.